GEP20053454B - Aryl Fused Azapolycyclic Compounds, Composition Containing the Same and Use Thereof - Google Patents

Aryl Fused Azapolycyclic Compounds, Composition Containing the Same and Use Thereof

Info

Publication number
GEP20053454B
GEP20053454B GE4911A GEAP2001004911A GEP20053454B GE P20053454 B GEP20053454 B GE P20053454B GE 4911 A GE4911 A GE 4911A GE AP2001004911 A GEAP2001004911 A GE AP2001004911A GE P20053454 B GEP20053454 B GE P20053454B
Authority
GE
Georgia
Prior art keywords
composition containing
same
aryl fused
fused azapolycyclic
azapolycyclic compounds
Prior art date
Application number
GE4911A
Other languages
English (en)
Inventor
Paige Roanne Palmer Brooks
Jotham Wadsworth Coe
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of GEP20053454B publication Critical patent/GEP20053454B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
GE4911A 2000-02-25 2001-02-08 Aryl Fused Azapolycyclic Compounds, Composition Containing the Same and Use Thereof GEP20053454B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/514,002 US6605610B1 (en) 1997-12-31 2000-02-25 Aryl fused azapolycyclic compounds

Publications (1)

Publication Number Publication Date
GEP20053454B true GEP20053454B (en) 2005-02-25

Family

ID=24045406

Family Applications (1)

Application Number Title Priority Date Filing Date
GE4911A GEP20053454B (en) 2000-02-25 2001-02-08 Aryl Fused Azapolycyclic Compounds, Composition Containing the Same and Use Thereof

Country Status (40)

Country Link
US (3) US6605610B1 (US07205300-20070417-C00007.png)
EP (2) EP1259489B1 (US07205300-20070417-C00007.png)
JP (1) JP2003524002A (US07205300-20070417-C00007.png)
KR (1) KR100537976B1 (US07205300-20070417-C00007.png)
CN (1) CN1263745C (US07205300-20070417-C00007.png)
AP (1) AP1860A (US07205300-20070417-C00007.png)
AT (2) ATE328872T1 (US07205300-20070417-C00007.png)
AU (2) AU784081B2 (US07205300-20070417-C00007.png)
BG (1) BG65891B1 (US07205300-20070417-C00007.png)
BR (1) BR0108610A (US07205300-20070417-C00007.png)
CA (1) CA2401229C (US07205300-20070417-C00007.png)
CR (1) CR6726A (US07205300-20070417-C00007.png)
CU (1) CU23148A3 (US07205300-20070417-C00007.png)
CY (1) CY1105301T1 (US07205300-20070417-C00007.png)
CZ (1) CZ303203B6 (US07205300-20070417-C00007.png)
DE (2) DE60120366T2 (US07205300-20070417-C00007.png)
DK (2) DK1619192T3 (US07205300-20070417-C00007.png)
DZ (1) DZ3328A1 (US07205300-20070417-C00007.png)
EA (1) EA005316B1 (US07205300-20070417-C00007.png)
EE (1) EE200200475A (US07205300-20070417-C00007.png)
ES (2) ES2263640T3 (US07205300-20070417-C00007.png)
GE (1) GEP20053454B (US07205300-20070417-C00007.png)
HK (1) HK1050894A1 (US07205300-20070417-C00007.png)
HR (1) HRP20020700A2 (US07205300-20070417-C00007.png)
HU (1) HU229482B1 (US07205300-20070417-C00007.png)
IL (2) IL150639A0 (US07205300-20070417-C00007.png)
IS (1) IS2293B (US07205300-20070417-C00007.png)
MA (1) MA26875A1 (US07205300-20070417-C00007.png)
MX (1) MXPA02008311A (US07205300-20070417-C00007.png)
NO (1) NO323608B1 (US07205300-20070417-C00007.png)
NZ (1) NZ519973A (US07205300-20070417-C00007.png)
OA (1) OA12181A (US07205300-20070417-C00007.png)
PL (1) PL365163A1 (US07205300-20070417-C00007.png)
PT (1) PT1259489E (US07205300-20070417-C00007.png)
RS (1) RS51123B (US07205300-20070417-C00007.png)
SI (1) SI1259489T1 (US07205300-20070417-C00007.png)
SK (1) SK12042002A3 (US07205300-20070417-C00007.png)
UA (1) UA74813C2 (US07205300-20070417-C00007.png)
WO (1) WO2001062736A1 (US07205300-20070417-C00007.png)
ZA (1) ZA200206768B (US07205300-20070417-C00007.png)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1044189B2 (en) * 1997-12-31 2015-02-25 Pfizer Products Inc. Aryl fused azapolycyclic compounds
AU2002234836B2 (en) * 2001-04-20 2007-08-23 Pfizer Products Inc. Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
WO2003037329A1 (en) * 2001-10-31 2003-05-08 Pfizer Products Inc. Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome
DK1448235T3 (da) * 2001-11-30 2007-07-02 Pfizer Prod Inc Orale, farmaceutiske sammensætninger af 5,8,14-triaza-tetracyclo[10.3.1.0(2,11).0(4.9)]-hexadeca-2(11),3,5,7,9-pentaen med kontrolleret frigivelse
IL161836A0 (en) * 2001-11-30 2005-11-20 Pfizer Prod Inc Aryl fused azapolycyclic compounds
KR101228376B1 (ko) 2002-07-18 2013-01-31 사이토스 바이오테크놀로지 아게 합텐-캐리어 컨쥬게이트 및 그의 용도
US7309458B2 (en) * 2002-10-22 2007-12-18 Millipore Corporation Multi-sided immersion formation of composite structures and method
RU2284319C2 (ru) * 2002-11-25 2006-09-27 Пфайзер Продактс Инк. Усовершенствованный способ получения 1,3-замещенных инденов
WO2004063164A1 (en) * 2003-01-15 2004-07-29 Pfizer Products Inc. Process for the preparation of aryl fused polycyclic lactams
MXPA05012507A (es) * 2003-05-20 2006-01-30 Pfizer Prod Inc Composiciones farmaceuticas de vareniclina.
PT1638971E (pt) * 2003-06-04 2008-10-23 Pfizer Prod Inc Preparação de quinoxalinas substituídas a partir da dianilina com 2,3-di-hidroxi-1,4-dioxano
CA2533100A1 (en) * 2003-07-21 2005-01-27 Pfizer Products Inc. Aryl fused azapolycyclic compounds
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
PL1677767T3 (pl) 2003-10-14 2011-12-30 Xenoport Inc Krystaliczna postać analogu kwasu gamma-aminomasłowego
JP2007516275A (ja) * 2003-12-23 2007-06-21 ファイザー・プロダクツ・インク 認知増強および精神病性障害のための治療的組合せ
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
ES2313625T3 (es) * 2005-02-24 2009-03-01 Pfizer Products Incorporated Preparacion de una quinoxalina sustituida de alta pureza.
WO2007122510A2 (en) * 2006-04-24 2007-11-01 Pfizer Products Inc. Asymmetric membranes for drug delivery devices
CA2666327A1 (en) * 2006-11-09 2008-05-22 Pfizer Products Inc. Polymorphs of nicotinic intermediates
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US20090062257A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched varenicline
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
WO2009065872A2 (en) * 2007-11-20 2009-05-28 Medichem, S.A. Improved processes for the synthesis of varenicline l-tartrate
RU2484090C2 (ru) * 2007-12-07 2013-06-10 Эбботт Гмбх Унд Ко.Кг 5-галогензамещенные производные оксиндола и их применение для лечения вазопрессинзависимых заболеваний
WO2010009775A1 (de) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
MX2010006204A (es) * 2007-12-07 2011-03-16 Abbott Gmbh & Co Kg Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
US8703775B2 (en) * 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
EP2271344A4 (en) 2008-03-31 2011-04-27 Univ South Florida METHODS OF TREATING DISEASE INDUCED ATAXIA AND NON-ATAXIC IMBALANCE
WO2009143347A2 (en) * 2008-05-22 2009-11-26 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
EP2334679A1 (en) * 2008-09-01 2011-06-22 Actavis Group PTC EHF Process for preparing varenicline, varenicline intermediates, and pharmaceutically acceptable salts thereof
CN102388043A (zh) * 2009-02-11 2012-03-21 桑诺维恩药品公司 组胺h3反相激动剂和拮抗剂及其使用方法
US9040568B2 (en) 2009-05-29 2015-05-26 Abbvie Inc. Pharmaceutical compositions for the treatment of pain
RU2012102052A (ru) * 2009-06-22 2013-11-20 Тева Фармасьютикал Индастриз Лтд. Твердые формы солей варениклина и способы их получения
JP7137850B2 (ja) 2017-03-03 2022-09-15 シーティーシー バイオ インク バレニクリンまたはその薬学的に許容可能な塩の包接複合体を含む口腔投与用製剤
US20230116114A1 (en) * 2020-01-03 2023-04-13 Blue Oak Pharmaceuticals, Inc. Compounds and compositions for treating cns disorders
CN115322105A (zh) * 2021-05-11 2022-11-11 江苏润安制药有限公司 一种合成艾拉莫德关键中间体的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
EP1044189B2 (en) * 1997-12-31 2015-02-25 Pfizer Products Inc. Aryl fused azapolycyclic compounds
EP0955301A3 (en) 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
ID26700A (id) 1998-04-29 2001-02-01 Pfizer Prod Inc Senyawa-senyawa azapolisiklik yang bercampur dengan aril
AU773795B2 (en) * 1999-01-29 2004-06-03 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
WO2002074050A2 (en) * 2001-03-19 2002-09-26 Sloan Kettering Institute For Cancer Research Asymmetric synthesis of (s, s, r)-(-)-actinonin and its analogs and uses therefor
CA2533100A1 (en) * 2003-07-21 2005-01-27 Pfizer Products Inc. Aryl fused azapolycyclic compounds
US8123947B2 (en) 2007-10-22 2012-02-28 Baxter International Inc. Priming and air removal systems and methods for dialysis

Also Published As

Publication number Publication date
HUP0204580A2 (hu) 2003-04-28
BR0108610A (pt) 2002-11-19
IS2293B (is) 2007-10-15
RS51123B (sr) 2010-10-31
CU23148A3 (es) 2006-06-29
OA12181A (en) 2006-05-09
DE60140965D1 (de) 2010-02-11
PT1259489E (pt) 2006-08-31
CA2401229A1 (en) 2001-08-30
EE200200475A (et) 2003-12-15
AP2002002604A0 (en) 2002-09-30
AP1860A (en) 2008-07-02
AU2005234671A1 (en) 2005-12-15
NO323608B1 (no) 2007-06-18
CN1406227A (zh) 2003-03-26
US20030130261A1 (en) 2003-07-10
HUP0204580A3 (en) 2005-04-28
ZA200206768B (en) 2003-09-23
CA2401229C (en) 2007-10-02
IL150639A0 (en) 2003-02-12
SK12042002A3 (sk) 2004-02-03
EP1619192A2 (en) 2006-01-25
CN1263745C (zh) 2006-07-12
AU784081B2 (en) 2006-02-02
SI1259489T1 (sl) 2006-10-31
CR6726A (es) 2003-10-28
KR20030005209A (ko) 2003-01-17
EP1619192B1 (en) 2009-12-30
US20030130260A1 (en) 2003-07-10
BG106908A (bg) 2003-04-30
MA26875A1 (fr) 2004-12-20
CZ303203B6 (cs) 2012-05-23
AU2874801A (en) 2001-09-03
NO20024042L (no) 2002-10-17
NZ519973A (en) 2004-04-30
EP1619192A3 (en) 2006-03-22
US7144882B2 (en) 2006-12-05
EP1259489B1 (en) 2006-06-07
AU2005234671B2 (en) 2008-04-17
ES2263640T3 (es) 2006-12-16
BG65891B1 (bg) 2010-04-30
EP1259489A1 (en) 2002-11-27
HK1050894A1 (en) 2003-07-11
DE60120366D1 (de) 2006-07-20
PL365163A1 (en) 2004-12-27
IS6459A (is) 2002-07-05
US7205300B2 (en) 2007-04-17
WO2001062736A1 (en) 2001-08-30
MXPA02008311A (es) 2002-12-09
NO20024042D0 (no) 2002-08-23
EA200200716A1 (ru) 2003-02-27
ATE453643T1 (de) 2010-01-15
IL150639A (en) 2011-10-31
UA74813C2 (en) 2006-02-15
DE60120366T2 (de) 2007-07-05
ATE328872T1 (de) 2006-06-15
HU229482B1 (en) 2014-01-28
CZ20022778A3 (cs) 2003-09-17
CY1105301T1 (el) 2010-03-03
DZ3328A1 (US07205300-20070417-C00007.png) 2001-08-30
US6605610B1 (en) 2003-08-12
DK1259489T3 (da) 2006-10-09
KR100537976B1 (ko) 2005-12-21
HRP20020700A2 (en) 2004-12-31
YU59602A (sh) 2005-06-10
ES2336800T3 (es) 2010-04-16
JP2003524002A (ja) 2003-08-12
DK1619192T3 (da) 2010-03-29
EA005316B1 (ru) 2004-12-30

Similar Documents

Publication Publication Date Title
GEP20053454B (en) Aryl Fused Azapolycyclic Compounds, Composition Containing the Same and Use Thereof
GEP20053673B (en) Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents
GEP20053530B (en) Tyrosine Kinase Inhibitors, Pharmaceutical Compositions Containing Them and Use Thereof
GEP20053479B (en) Pyrrolo[2,3-d]Pyrimidine Compounds, Pharmaceutical Composition Containing the Same and Use
GEP20043241B (en) Compounds for Treatment of Ischemia and Pharmaceutical Compositions Containing the Same
NZ324887A (en) Piperazine and piperidine compounds with analgesic effect
GEP20032896B (en) 4-Aminothiazole Derivatives, Containing Them Pharmaceutical Compositions Inhibiting Cyclin-Dependent Kinases and Methods for Treatment
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
GEP20043324B (en) Purine Derivatives
MY119403A (en) Novel compounds with analgesic effect.
GEP20033118B (en) Meta-Azacyclic Amino Benzoic Acid Compounds and Derivatives Thereof Being Integrin Inhibitors, Pharmaceutical Composition and Use Thereof
GEP20043315B (en) Non-Peptide GnRH Agents, Methods For Their Preparation and Use Thereof
NZ501066A (en) Pharmaceutical formulations containing voriconazole and sulphobutylether beta-cyclodextrin
JO2354B1 (en) New derivatives of aromatic fluoroglycosides and drugs containing these compounds and their use
HU229443B1 (en) Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use
GEP20043179B (en) Halogenated Amidino Amino Acid Derivatives Useful as Nitric Oxide Synthase Inhibitors
GEP20033079B (en) Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency
GEP20043383B (en) Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds
GEP20053626B (en) Substituted 8-Arylquinoline Phosphodiesterase-4 Inhibitors, Pharmaceutical Composition Containing Them and Use Thereof
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
WO2003051274A3 (en) Benzodiazepine derivatives, preparation thereof and use thereof
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
KR960703863A (ko) 암 치료용 신규 비스-나프탈이미드(New Bis-naphthalimides for the Treatment of Cancer)
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
GEP20063754B (en) Quinoline Derivatives and Use Thereof as Antitumor Agents